Guide

Zepbound for sleep apnea: who the approval covers and what the trials showed

Zepbound® (tirzepatide) is FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity.1 In the trials behind that approval, those words came down to two numbers: at least 15 breathing events an hour on a sleep study, and a BMI (body mass index) of at least 30.2

Get Started

General health education, not medical advice. Keep using CPAP or any other prescribed treatment until your sleep clinician changes it.

Key points

  • The approval dates from December 20, 2024. Central sleep apnea is not on the label.
  • Over 52 weeks, Zepbound groups lost 25.3 and 29.3 breathing events an hour. Placebo groups lost 5.3 and 5.5.
  • It is not a stand-in for CPAP. When PAP therapy can stop was never tested.
  • The target weekly dose is 10 or 15 mg, reached in steps.

Has the FDA approved Zepbound for sleep apnea?

It has, since December 20, 2024. The indication is narrow: the obstructive form (OSA), at a moderate or severe level, in adults who have obesity, with diet and exercise changes alongside. Before it, the FDA had never approved a medication for OSA.1

The label lists one other use, long-term weight management.2 The drug is identical, but the reason written on the prescription matters once insurance is involved.

Exactly who the approval is for

  • The obstructive type. Something blocks airflow through the upper airway during sleep.3
  • Moderate to severe. The supporting trials set the bar at 15 events an hour on the apnea-hypopnea index (AHI).2
  • Adult, with obesity. Those trials required a BMI of 30 or more.2

What the label does not cover

  • Central sleep apnea, which stems from how the brain controls breathing during sleep.3 The label names the obstructive type only.2
  • Mild OSA, and OSA in someone whose BMI is below 30.
  • Snoring or tiredness that nobody has diagnosed.
  • Children. Safety and effectiveness are not established in pediatric patients.2

How does Zepbound help sleep apnea?

Mostly through weight loss. In its approval notice the FDA tied the improvement in AHI to the body weight people lost, calling the link likely.1

Extra fat deposits in the neck can block the upper airway, which is why NHLBI, the federal heart, lung and blood institute, counts obesity as a risk factor.3 Tirzepatide acts at the GIP and GLP-1 hormone receptors and lowers calorie intake, probably through appetite.2

Timing. Your airway is no different on injection night. Doses climb over as long as 20 weeks and the trials took their main reading at week 52,2 so keep your current sleep apnea treatment going meanwhile.

Zepbound sleep apnea trial results, with and without PAP therapy

By week 52, Zepbound had cut breathing events by 25.3 an hour in one trial and 29.3 in the other. Placebo cut them by 5.3 and 5.5.2

The pair of trials, named SURMOUNT-OSA, enrolled 469 adults, none with type 2 diabetes. Trial 1 was for people not using a positive airway pressure (PAP) machine, 234 of them. Trial 2 was for 235 people already on one. Half of each trial received the highest Zepbound dose they tolerated, 10 or 15 mg weekly, and everyone received diet and activity counseling.2 Eli Lilly funded both.4

Starting AHIs averaged 51.5 and 49.5, and 63.1% and 68.2% of participants were in the severe range.2

At week 52Zepbound vs placeboTrial 1no PAPTrial 2on PAP
AHI change, events an hour−25.3 vs −5.3−29.3 vs −5.5
AHI change, percent−50.7% vs −3.0%−58.7% vs −2.5%
AHI at least halved61.2% vs 19%72.4% vs 23.3%
Remission or mild, symptom-free OSA42.2% vs 15.9%50.2% vs 14.3%
Body weight change−17.7% vs −1.6%−19.6% vs −2.3%

Zepbound first, then placebo. The remission row counts an AHI below 5, or 5 to 14 plus an Epworth Sleepiness Scale score no higher than 10. Label, Table 9.2 Individual results vary.

The label also reports larger falls in systolic blood pressure and in a blood marker of inflammation on Zepbound.2

What a 25 to 29 point drop leaves behind

A big fall from a high start can still leave sleep apnea that needs treating. The Zepbound groups began at average AHIs of 52.9 and 46.1.2 Take off 25.3 and 29.3 and you get roughly 28 and 17 events an hour, both still moderate.

That is arithmetic on averages, not a forecast for anyone. On Zepbound, 42.2% and 50.2% reached the table’s remission row. The rest did not.2

AHI ranges on a sleep study report

AHI is how many times an hour breathing stops or is partly blocked for 10 seconds or longer. For adults, MedlinePlus puts normal below 5, mild at 5 to 14, moderate at 15 to 29 and severe at 30 and up.5

Do you qualify for Zepbound for sleep apnea?

The approved use fits an adult with obesity whose OSA has been diagnosed as moderate or severe.2 Prescribers look at three things:

  1. Your sleep study. It should show the obstructive type, with an AHI of 15 or higher.
  2. Your BMI. It should be 30 or higher. Our BMI calculator works it out.
  3. Your history. No medullary thyroid carcinoma in you or your family, no MEN 2, and no serious allergy to tirzepatide.2

Not tested yet?

See a clinician first. A diagnosis takes a sleep study, read by a specialist alongside your history and an exam. Loud snoring, pauses in breathing followed by gasps, and daytime sleepiness are reasons to ask. Some studies can be done at home.5 This page cannot diagnose you.

Mild OSA, or a BMI below 30?

Then this indication is closed to you, though weight management may be open. Zepbound’s weight trials accepted a BMI of 27 to under 30 when a weight-related condition was present, and OSA was among the conditions named.2 The Zepbound page covers that use.

Where AM Rx comes in

AM Rx is an online weight loss program for eligible adults in all 50 states and Washington, DC. A licensed provider reads your health questionnaire within 1 to 2 business days and replies by secure message. Starting does not require a live appointment.

Our providers prescribe brand-name GLP-1 medications, Zepbound among them, when one is appropriate for you. Mention any sleep apnea diagnosis in the questionnaire. PAP settings and sleep studies stay with your sleep clinician.

Get Started

What Zepbound dose treats sleep apnea?

For sleep apnea the label sets maintenance at 10 or 15 mg a week, given under the skin, with 15 mg as the ceiling. Treatment opens with four weeks at 2.5 mg, then 5 mg. After that, each 2.5 mg rise needs at least four weeks on the dose before.2

WeeksWeekly doseRole in sleep apnea treatment
Weeks 1 to 42.5 mgLead-in only, not for long-term use
Weeks 5 to 85 mgRequired step. Long-term dose for weight, not for OSA
Weeks 9 to 127.5 mgBridge to 10 mg
Weeks 13 to 1610 mgLower long-term dose for OSA
Weeks 17 to 2012.5 mgBridge to 15 mg
Week 21 on15 mgUpper long-term dose, also the maximum

The fastest timetable the label allows. A prescriber can hold any step longer, or settle lower when side effects are a problem.2

Pick one day of the week and keep to it. Inject into the abdomen or thigh, or have someone else use the back of your upper arm. A missed dose can be taken up to 4 days (96 hours) late. Beyond that, skip it.2 The Zepbound dosing section covers pens and storage.

Does Zepbound replace a CPAP machine?

No, not on the evidence so far. The label says outright that the trials never looked at when, or whether, PAP should be stopped in people who had been using it.2

CPAP keeps the airway open with constant air pressure, and NHLBI calls PAP machines the most common treatment for sleep apnea.6 Zepbound works on weight, over months.

QuestionZepboundCPAP
What does it do?Lowers weight, which in trials went with fewer breathing eventsHolds the airway open with air from a mask
When does it help?Gradually, over monthsDuring the sleep you wear it for, naps included
Common complaintsNausea, diarrhea, vomiting, constipationCongestion, dry mouth or eyes, nosebleeds, runny nose

Zepbound: Prescribing Information.2 CPAP: NHLBI.6,7

What the trial of PAP users did and did not test

Everyone in trial 2 was on PAP. With Zepbound added, AHI came down 29.3 events an hour, against 5.5 on placebo. PAP users were asked to leave the machine off for the 7 days leading up to the last sleep study, so their breathing was recorded without it.2 That was a supervised measurement step, not advice to try a week without yours.

NHLBI says a repeat sleep study may be needed after losing or gaining a lot of weight.7 If yours drops substantially, ask about retesting. Feeling rested is not proof that the airway stays open.

Do not stop CPAP on your own. NHLBI links untreated sleep apnea to hard-to-control high blood pressure, heart attack and stroke, and to sleepiness that can cause road accidents.7

If you cannot use CPAP

Trial 1 was made up entirely of people not on PAP, and their AHI fell by 25.3 events an hour, against 5.3 on placebo.2 Even so, ask your clinician about a different mask, new machine settings, or an oral device fitted by a dentist.6,7

Is Zepbound for sleep apnea covered by insurance or Medicare?

Sometimes, depending on the kind of insurance. OSA has its own line on the label, so a plan can treat it differently from weight loss. Everything below is as of November 2026.

Commercial and employer plans

Rules differ by plan, so check its drug list, and keep your sleep study report handy for any prior authorization.

Lilly’s savings card can take a covered single-dose pen fill down to $25, saving at most $100 on a one-month fill. The card ends December 31, 2026 and is closed to people with government coverage such as Medicare, Medicaid, TRICARE or VA.8

For AM Rx members, our insurance coordinators send the prior authorization for a brand-name prescription. A decision usually takes 2 to 14 business days, and when your plan covers the drug your copay may be as little as $25 a month. We cannot promise approval. Start with the GLP-1 insurance checker.

Medicare and Medicaid

Medicare drug plans can cover Zepbound for sleep apnea. The Centers for Medicare & Medicaid Services (CMS) treats moderate to severe OSA as an indication eligible for Part D coverage, and says a plan must use its formulary exception process when the drug is off its list.9 Confirm with your plan.

The $50-a-month Medicare GLP-1 Bridge, which runs through December 31, 2027, is for weight management only. CMS says people with this diagnosis are not eligible for it.9

Medicaid differs. According to KFF, states have to cover Zepbound for this use, although prior authorization is typical.10

Paying without coverage

Through LillyDirect, Lilly’s direct pharmacy service, self-pay costs $299 for 28 days of the KwikPen or vials at 2.5 mg, and $399 at 5 mg. The 10 mg and 15 mg doses cost $449 when each refill is bought within 45 days of the last, and $699 when it is not.11 See Zepbound costs in full.

Compounded tirzepatide is not FDA-approved for any use, and the FDA does not review compounded medications for their safety, effectiveness or quality.12 The results here are from Zepbound trials only.

Zepbound side effects and safety for people with sleep apnea

Nothing new showed up. At 10 and 15 mg, the label says, people in the sleep apnea trials had much the same reactions as people in the weight trials, and the trial report calls them mostly gastrointestinal and mild to moderate.2,4

Side effect10 mg15 mgPlacebo
Nausea29%28%8%
Diarrhea21%23%8%
Constipation14%11%5%
Vomiting11%13%2%

The two sleep apnea doses in pooled weight trials (SURMOUNT-1 and SURMOUNT-2), label Table 1.2 Stomach effects clustered around dose increases and eased with time.

Two points that matter more with sleep apnea

  • Operations and sedation. Zepbound delays stomach emptying, and there are rare reports of stomach contents reaching the lungs under anesthesia with this drug class.2 Sleep apnea itself calls for extra airway precautions.7 Tell the anesthesia team about both.
  • Sudden vision changes. On November 9, 2026 the FDA said GLP-1 labels, Zepbound’s included, must warn of a possible raised risk of NAION, a rare cause of sudden vision loss in one eye. The notice names sleep apnea as a possible risk factor for NAION itself. That is a point about the eye condition, not about the drug in people with sleep apnea.13

The boxed warning is in the safety information below. More: Zepbound side effects and all GLP-1 side effects.

Zepbound and sleep apnea: questions people ask

Will Zepbound make my sleep apnea go away completely?

For some people, but not most. At week 52, 42.2% of participants in one trial and 50.2% in the other had an AHI below 5, or a mild reading with no daytime sleepiness. Placebo figures were 15.9% and 14.3%. Individual results vary.

Can Zepbound take the place of my CPAP?

Only if your sleep clinician decides so after retesting. When PAP can safely stop was never part of the Zepbound trials, and group averages still sat in the moderate range after a year. Keep using your machine until that happens.

How long does Zepbound take to improve sleep apnea?

Plan on months. Reaching 10 mg, the lower sleep apnea dose, takes 12 weeks at the fastest, and the trials measured their main result at week 52. The benefit follows weight loss, so it builds slowly, and only a sleep study can confirm it.

Is Zepbound approved for mild or central sleep apnea?

No. The label covers only the obstructive type, at moderate or severe level, in adults who have obesity. Central sleep apnea is never mentioned. With mild OSA and a BMI of 27 or more, the separate weight management approval may apply.

Is a sleep study required to get Zepbound for sleep apnea?

Yes, for this use. The approval depends on which type of sleep apnea you have and how severe it is. Both come from a sleep study that a clinician orders and interprets. Some sleep studies can be done at home.

Does Medicare Part D pay for Zepbound for sleep apnea?

It can, depending on your plan. CMS treats this diagnosis as an indication eligible for Part D coverage. Plans still set their own drug lists and requirements. The $50 Medicare GLP-1 Bridge is closed to people with moderate to severe OSA.

Is Mounjaro approved for sleep apnea too?

No. Mounjaro® and Zepbound both contain tirzepatide and both come from Eli Lilly, but Mounjaro is labeled for type 2 diabetes.14 Of the two, only Zepbound carries the sleep apnea approval. Our tirzepatide page sets the brands side by side.

What happens to sleep apnea if I stop taking Zepbound?

The label has no data on sleep apnea after stopping. Weight has been studied. In the SURMOUNT-4 trial, people moved from tirzepatide to placebo regained 14.0% of their weight over the next 52 weeks.15 Talk to your prescriber and sleep clinician first.

Important safety information for Zepbound

A plain-language summary of the Prescribing Information, not a replacement for it.2

Boxed warning: risk of thyroid C-cell tumors

Tirzepatide caused thyroid C-cell tumors in rats. Whether Zepbound causes them in people, including medullary thyroid carcinoma (MTC), is unknown. Do not use it if you or a family member has had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath.

Do not use Zepbound if

  • the boxed warning above applies to you
  • you have had a serious allergic reaction to tirzepatide or another ingredient

Tell your provider first if you

  • have had pancreas problems, severe stomach problems such as gastroparesis, or diabetic retinopathy
  • have surgery or a procedure with anesthesia or deep sedation planned
  • are pregnant, breastfeeding, or planning either
  • take insulin, a sulfonylurea or birth control pills

Serious side effects

Severe stomach problems. Kidney problems from dehydration. Gallbladder problems. Inflammation of the pancreas. Serious allergic reactions. Low blood sugar, mainly alongside insulin or a sulfonylurea. Vision changes in people with type 2 diabetes. Food or liquid entering the lungs during anesthesia. The FDA is also adding a warning about NAION, a rare eye condition.13

Most common side effects

Nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, tiredness, allergic reactions, belching, hair loss and heartburn.

Pregnancy and birth control

Zepbound may harm an unborn baby. Stop it when pregnancy is recognized. Birth control pills may work less well, so use a non-oral or added barrier method for 4 weeks after starting and after each dose increase.

Also

Do not combine Zepbound with another tirzepatide product or any GLP-1 receptor agonist, and never share a KwikPen. Report side effects to the FDA at 1-800-FDA-1088.

Call 911 or go to an emergency room if you have trouble breathing, swelling of the face or throat, severe stomach pain that will not ease, or sudden loss of vision.

Sources

  1. FDA. FDA Approves First Medication for Obstructive Sleep Apnea. December 20, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
  2. Zepbound (tirzepatide) Prescribing Information. Eli Lilly. Revised 08/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
  3. NHLBI. Sleep Apnea: Causes and Risk Factors. Updated January 9, 2025. https://www.nhlbi.nih.gov/health/sleep-apnea/causes
  4. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. https://pubmed.ncbi.nlm.nih.gov/38912654/
  5. MedlinePlus Medical Encyclopedia. Polysomnography. Reviewed May 4, 2026. https://medlineplus.gov/ency/article/003932.htm
  6. NHLBI. Sleep Apnea: Treatment. Updated January 9, 2025. https://www.nhlbi.nih.gov/health/sleep-apnea/treatment
  7. NHLBI. Sleep Apnea: Living With. Updated January 9, 2025. https://www.nhlbi.nih.gov/health/sleep-apnea/living-with
  8. Eli Lilly. Zepbound savings options and Savings Card terms. Accessed November 19, 2026. https://zepbound.lilly.com/savings
  9. CMS. Medicare GLP-1 Bridge: Information for Part D Plans. Accessed November 19, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
  10. KFF. Medicaid Coverage of and Spending on GLP-1s. January 16, 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
  11. Eli Lilly. Zepbound through LillyDirect. Accessed November 19, 2026. https://www.lilly.com/lillydirect/zepbound
  12. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Current as of October 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  13. FDA. Drug Safety Communication: GLP-1 receptor agonists and a rare eye condition (NAION). November 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  14. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly. Revised 08/2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
  15. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/

Ask a licensed provider whether Zepbound suits you

The health questionnaire takes a few minutes and is read by a licensed provider. Your first month of AM Rx membership is $39.

Get Started
A man at home smiling at his laptop
Your care team

Weight care from AM Rx, beside your sleep clinician

An AM Rx provider reads your health history online and prescribes a GLP-1 medication such as Zepbound only when it is appropriate for you. PAP therapy and repeat sleep studies stay with the clinician who looks after your sleep apnea.

50 states and DCU.S.-licensed physicians and nurse practitioners, wherever you live
No appointment to bookA provider reads your intake online and replies by secure message
Open every dayPhone support Monday to Friday 9am to 8pm ET, weekends 12pm to 8pm ET

The AM Rx care team checks the medical content of this page against FDA prescribing information and published clinical trials. It is general health education and does not replace advice from your own provider.

AM Rx members

AM Rx members, in their own words

One of the things I appreciate most about semaglutide is its convenience. The once-weekly dosing schedule has made it incredibly easy to integrate into my routine. It's a relief to know that I don't have to worry about multiple daily injections or complicated medication schedules.
Michelle, 33 | Lost 48 pounds
I started semaglutide at the recommendation of my AM Rx provider and I'm so happy with that decision. I signed up for their weight loss program and they've been giving me everything I need to make better lifestyle choices to get results that last. And the program's super affordable. 10/10 I can't recommend this enough.
Michael, 37 | Lost 29 pounds
Getting support a weight loss program has always been hard for me. I had been wanting to start one with a medication component for a while and AM Rx was the first one that made it easy for me with weight loss shots sent to me. They made it SO affordable and the medical team is great.
Susanne, 60 | Lost 33 pounds
Since I started AM Rx, I have already lost 35 pounds and feel so much better. My doctor also helped me get a prescription for ozempic and he is always available to answer my questions in the message portal. This made me feel a lot more comfortable and excited to lose weight.
Rachel | AM Rx Member
The weight loss program is fantastic. Everyone has been so helpful and has helped me feel much more excited about the process. I was nervous to see my weight loss treatment plan, since I have done programs in the past, but they always wanted me to make drastic changes. I mentioned all of this to my weight loss coach and she was very understanding and made a customized plan for me.
John | AM Rx Member
I've been a member for 6 months now and have received all my medication every 3 months. Everyone has been so helpful and my care team is always available to help me!
Sara | AM Rx Member

Individual results may vary. These reviews describe the experience of individual AM Rx members and do not promise any result. Medication is prescribed only if a licensed provider considers it appropriate.

Medications

The GLP-1 medications AM Rx providers prescribe

Four brand-name medications and two compounded options. Which one you are offered depends on your health history and a licensed provider’s judgment, and our insurance coordinators file the prior authorization when a brand-name drug is prescribed.

A partner pharmacy prepares compounded medication for one patient’s prescription at a time. Compounded drugs are not FDA-approved: the FDA does not review them for safety, effectiveness or quality. AM Rx membership costs $39 for the first month and $135 a month after that, and is charged separately from medication. Nothing is prescribed unless a licensed provider finds it appropriate.